Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$41.10 USD

41.10
1,277,780

+0.37 (0.91%)

Updated Jun 27, 2024 04:00 PM ET

After-Market: $41.12 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

QIAGEN Ships Test Kits to China for Detecting Coronavirus

QIAGEN (QGEN) expands the molecular testing portfolio by shipping QIAstat-Dx Respiratory 2019-nCoV Panel to China for faster detection of coronavirus SARS-CoV-2.

Sriparna Ghosal headshot

Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe

QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand

QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4

Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?

ALXN vs. QGEN: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.

Company News For Dec 27, 2019

Companies In The News Are: QGEN, IMMU, CANF, SBPH

OSMT vs. QGEN: Which Stock Should Value Investors Buy Now?

OSMT vs. QGEN: Which Stock Is the Better Value Option?

QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus

QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.

QIAGEN Expands Existing Deal With LabCorp for Better Treatment

QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.

OSMT or QGEN: Which Is the Better Value Stock Right Now?

OSMT vs. QGEN: Which Stock Is the Better Value Option?

QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes

QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.

QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%

QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

QIAGEN (QGEN) Beats Q3 Earnings Estimates, Cuts Revenue View

We are impressed with QIAGEN's (QGEN) year-over-year growth across majority of operating segments in Q3.

Qiagen (QGEN) Tops Q3 Earnings Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 2.86% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Q3 Earnings Preview: What's in the Cards?

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN (QGEN) Launches QIAseq FastSelect Technology Kits

The launch of the kits is expected to bolster QIAGEN's (QGEN) Life Sciences Business Area

QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure

If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.

QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits

QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.

Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind

Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.

Qiagen (QGEN) Down 8.7% Since Last Earnings Report: Can It Rebound?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN Posts QIAstat-Dx Gastrointestinal Panel Study Results

The study outcome has been a major step for QIAGEN (QGEN) toward offering accurate diagnosis and treatment of gastroenteritis.